Related Experiment Video
Updated: Jul 6, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Proteasome inhibitor does not enhance MPTP neurotoxicity in mice
Naoto Kadoguchi1, Masahiro Umeda, Hiroyuki Kato
1Department of Neurobiology and Therapeutics, Graduate School and Faculty of Pharmaceutical Sciences, The University of Tokushima, 1-78 Sho-machi, Tokushima 770-8505, Japan.
Abstract:
Dysfunction of the proteasome function is known to be a potential mechanism for dopaminergic neuron degeneration. Here, we investigated to determine whether systematic administration of proteasome inhibitor, carbobenzoxy-L-gamma-t-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI), causes the increased susceptibility in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. PSI was injected into MPTP-treated mice over a period of 2 weeks. Thereafter, we evaluated the effect of PSI 2, 4, and 8 weeks after the cessation of treatment with PSI. In the present study with HPLC analysis, PSI did not enhance MPTP-induced dopaminergic neurotoxicity in mice. Our present study with Western blot analysis also demonstrated that the reduction of tyrosine hydroxylase (TH) and glial fibrillary acidic protein (GFAP) protein levels in MPTP-treated mice was more pronounced than that in MPTP + PSI-treated animals. These results suggest that proteasome inhibitor did not enhance MPTP neurotoxicity in mice. Our findings suggest that proteasome inhibition is not a reliable model for PD. Thus, our findings provide further valuable information for the pathogenesis of Parkinson's disease.
Insights
Proteasome inhibitor carbobenzoxy-L-gamma-t-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI) did not worsen 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice. These findings indicate proteasome inhibition is not a reliable model for Parkinson's disease pathogenesis.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Proteasome dysfunction is implicated in dopaminergic neuron degeneration.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin used to model Parkinson's disease.
- Proteasome inhibitors are being investigated for their role in neurodegenerative diseases.
Purpose of the Study:
- To investigate if proteasome inhibitor carbobenzoxy-L-gamma-t-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI) increases susceptibility in MPTP-treated mice.
- To evaluate the long-term effects of PSI administration on MPTP-induced neurotoxicity.
- To determine the reliability of proteasome inhibition as a model for Parkinson's disease (PD) pathogenesis.
Main Methods:
- MPTP-treated mice were administered PSI for two weeks.
- High-Performance Liquid Chromatography (HPLC) was used to analyze dopaminergic neurotoxicity.
- Western blot analysis was performed to assess tyrosine hydroxylase (TH) and glial fibrillary acidic protein (GFAP) levels.
Main Results:
- PSI administration did not enhance MPTP-induced dopaminergic neurotoxicity.
- MPTP-treated mice showed a more pronounced reduction in TH and GFAP protein levels compared to MPTP + PSI-treated mice.
- These results suggest a potential protective effect or no exacerbation of neurotoxicity by PSI.
Conclusions:
- Proteasome inhibition with PSI does not exacerbate MPTP-induced neurotoxicity in mice.
- The findings suggest that proteasome inhibition is not a suitable animal model for studying Parkinson's disease.
- This study provides valuable insights into the complex pathogenesis of Parkinson's disease.
